Analysis of the Association Between Polymorphisms within PAI-1 and ACE genes and Ischemic Stroke Outcome After rt-PA Therapy

Authors

  • Marija Dušanović Pjević Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Serbia.
  • Ljiljana Beslac Bumbaširevic Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Serbia.
  • Ljubica Vojvodic St. Sava Hospital, Belgrade, Serbia.
  • Milka Grk Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Serbia.
  • Nela Maksimović Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Serbia.
  • Tatjana Damnjanović Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Serbia.
  • Ivana Novaković Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Serbia.
  • Katarina Kačar St. Sava Hospital, Belgrade, Serbia.
  • Milica Pesic Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Serbia.
  • Dijana Perovic Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Serbia.
  • Milan Savic St. Sava Hospital, Belgrade, Serbia.
  • Veljko Maksic St. Sava Hospital, Belgrade, Serbia.
  • Jelena Trickovic St. Sava Hospital, Belgrade, Serbia.
  • Biljana Jekic Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Serbia.

DOI:

https://doi.org/10.18433/jpps30339

Abstract

Purpose: Treatment of Ischemic stroke (IS) in acute phase is based on the use of thrombolytic rt-PA therapy. We aimed to determine whether different alleles and genotypes of I/D ACE gene and 4G/5G PAI-1 gene polymorphisms may influence outcome of rt-PA therapy in patients with IS and the occurrence of haemorrhagic transformation (HT). Methods: Our study included 94 consecutive patients with IS treated with rt-PA. Modified Rankin Scale (mRS) at 3rd month after IS was used to determine the stroke outcome, with scores 0-1 defining the favourable outcome, and scores 2-6 defining poor outcome. Genotypisation of the ACE-1 I/D polymorphism was performed by polymerase chain reaction and of the PAI-1 4G/5G polymorphism by polymerase chain reaction - restriction fragment length analysis. Results: Regarding PAI-I 4G/5G polymorphism, 44 patients (46.8%) were heterozygotes, and the number of 4G/4G and 5G/5G homozygotes was the same – 25 each (26.6%). Number of heterozygotes for the ACE I/D polymorphism was 54 (57.4%), 9 patients (9.6%) had II, and 31 (33%) DD genotypes. A favourable outcome was recorded in 26 (28.0%) and the poor outcome in 67 (72.0%) patients. Favourable and poor outcome groups did not differ significantly in PAI-1 4G/5G and ACE I/D polymorphisms genotype or allele frequencies. There was a statistically significant difference in the occurrence of HT between patients with ACE II and patients with ACE ID or DD genotypes (p=0.035). Conclusion: Results of our study suggest that stroke patients with ACE II genotype, treated with rt-PA, may be at risk of HT.

Downloads

References

Sacco R, Kasner S, Broderick J, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44:2064-89. doi: 10.1161/STR.0b013e318296aeca.

Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2095–128. doi: 10.1016/S0140-6736(12)61728-0.

Murray C, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2197–223. doi: 10.1016/S0140-6736(12)61689-4.

Medic S, Beslac-Bumbasirevic L, Kisic-Tepavcevic D, et al. Short-term and long-term stroke survival: the Belgrade prognostic study. J Clin Neurol. 2013; 9(1):14-20. doi: 10.3988/jcn.2013.9.1.14.

Boehme A, Esenwa C, Elkind M. Stroke Risk Factors, Genetics, and Prevention. Circ Res.2017; 120:472-495. doi: 10.1161/CIRCRESAHA.116.308398.

Li S, Zhao X, Wang C, et al. Risk factors for poor outcome and mortality at 3 months after the ischemic stroke in patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2013; 22(8):e419-25. doi: 10.1016/j.jstrokecerebrovasdis.2013.04.025.

Astrup J. Energy-requiring cell functions in the ischemic brain. Their critical supply and possible inhibition in protective therapy. Journal of neurosurgery. 1982; 56:482–497. DOI:10.3171/jns.1982.56.4.0482

Acheampong P, Ford G. Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol. 2012; 8:271-81. doi: 10.1517/17425255.2012.652615.

Del Zoppo GJ, Saver JL, Jauch EC, et al. American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40:2945-8. doi: 10.1161/STROKEAHA.109.192535.

Bivard A, Lin L, Parsons MW. Review of Stroke Thrombolytics. Journal of Stroke. 2013; 15(2):90-98. doi: 10.5853/jos.

Jauch E, Saver J, Adams, H, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44:870-947. doi: 10.1161/STR.0b013e318284056a.

Erdos E, Skidgel R. The angiotensin I-converting enzyme. Lab Invest. 1987;56:345–348.

Crisan D, Carr J. Angiotensin I-converting enzyme: genotype and disease associations. J Mol Diagn. 2000; 2:105–115. DOI:10.1016/S1525-1578(10)60624-1

Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86:1343-6.

Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. ArteriosclerThromb Vasc Biol. 2000; 20:484–92.

Lijnen H. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost. 2005; 3:35-45. DOI:10.1111/j.1538-7836.2004.00827.x

Dawson S, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993; 268:10739-45.

Weisscher N, Vermeulen M, Roos YB, et al. What should be defined as good outcome in stroke trials; a modified Rankin score of 0-1 or 0-2? J Neurol. 2008; 255:867-74. doi: 10.1007/s00415-008-0796-8.

Rao NM, Levine SR, Gornbein JA, et al. Defining Clinically Relevant Cerebral Hemorrhage After Thrombolytic Therapy for Stroke: Analysis of the NINDS-tPA Trials. Stroke. 2014; 45(9):2728-33. doi: 10.1161/STROKEAHA.114.005135.

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16:1215.

Carty C, Buzková P, Fornage M, et al. Associations between incident ischemic stroke events and stroke and cardiovascular disease-related genome-wide association studies single nucleotide polymorphisms in the Population Architecture Using Genomics and Epidemiology study. Circ Cardiovasc Genet. 2012; 5:210-6. doi: 10.1161/CIRCGENETICS.111.962191.

Karki R, Pandya D, Elston R, et al. Defining "mutation" and "polymorphism" in the era of personal genomics. BMC Med Genomics. 2015; 8:37. doi: 10.1186/s12920-015-0115-z.

Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation. 1995; 92:1387-8.

Wang XL, McCredie RM, Wilcken DE. Genotype distribution of angiotensin-converting enzyme polymorphism in Australian healthy and coronary populations and relevance to myocardial infarction and coronary arterydisease. Arterioscler Thromb Vasc Biol. 1996; 16:115– 119.

Hasan A, Lansburry A, Catto AJ, et al. Angiotensin converting enzyme insertion/deletion is associated with leukoraiosis in lacunar syndromes. J Neurol Neurosurg Psychiatry. 2002; 72:343–6.

Kalita J, Somarajan B, Kumar B, et al. A study of ACE and ADD1 polymorphism in ischemic and hemorrhagic stroke. Clin Chim Acta. 2011; 412:642-6. doi: 10.1016/j.cca.2010.12.022.

Yuan H, Wang X, Xia Q, et al. Angiotensin converting enzyme (I/D) gene polymorphism contributes to ischemic stroke risk in Caucasian individuals: A meta-analysis based on 22 case-control studies. Int J Neurosci. 2015; 1-24. doi: 10.3109/00207454.2015.1036421.

Tuncer N, Tuglular S, Kilic G, et al. Evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of ischaemic stroke. J Clin Neurosci. 2006; 13:224-7. DOI:10.1016/j.jocn.2005.08.005

Domingues-Montanari S, Fernandez-Cadenas I, del Rio-Espinola A, et al. The I/D polymorphism of the ACE1 gene is not associated with ischaemic stroke in Spanish individuals. Eur J Neurol. 2010; 17:1390-2. doi: 10.1111/j.1468-1331.2010.03022.x.

Malueka RG, Dwianingsih EK, Sutarni S, et al. The D allele of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism is associated with worse functional outcome of ischaemic stroke. Int J Neurosci. 2017; 1-8. doi: 10.1080/00207454.2017.1412962

Fernández-Cadenas I, Molina CA, Alvarez-Sabín J, et al. ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neurosci Lett. 2006; 398:167-71. DOI:10.1016/j.neulet.2005.12.079

Douglas E. Vaughan. Angiotensin, Fibrinolysis, and Vascular Homeostasis. Am J Cardiol. 2001; 87:18C–24C.

Hu X, Zan X, Xie Z, et al. Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility. Mol Neurobiol. 2017; 328-341. DOI:10.1007/s12035-015-9549-8

Cao Y, Chen W, Qian Y, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and ischemic stroke risk: a meta-analysis in Chinese population. Int J Neurosci. 2014; 124:874-81. doi: 10.3109/00207454.2014.886577

Fernandez-Cadenas I, Del Rio-Espinola A, Rubiera M, et al. PAI-1 4G/5G polymorphism is associated with brain vessel reocclusion after successful fibrinolytic therapy in ischemic stroke patients. Int J Neurosci. 2010; 120:245-51. DOI:10.3109/00207451003597169

Downloads

Published

2019-04-23

How to Cite

Dušanović Pjević, M., Beslac Bumbaširevic, L., Vojvodic, L., Grk, M., Maksimović, N., Damnjanović, T., … Jekic, B. (2019). Analysis of the Association Between Polymorphisms within PAI-1 and ACE genes and Ischemic Stroke Outcome After rt-PA Therapy. Journal of Pharmacy & Pharmaceutical Sciences, 22(1), 142–149. https://doi.org/10.18433/jpps30339

Issue

Vol. 22 (2019): Pages 131 - 364

Section

Pharmaceutical Sciences; Original Research Articles

License

This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.

CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.